The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Journal of Experimental & Clinical Cancer Research volume 39, Article number: 284 (2020)
The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle to the prospect of ICI treatment. IrAEs are a discrete toxicity caused by the nonspecific activation of the immune system and can affect almost all tissues and organs. Currently, research on biomarkers mainly focuses on the gastrointestinal tract, endocrine system, skin and lung. Several potential hypotheses concentrate on the overactivation of the immune system, excessive release of inflammatory cytokines, elevated levels of pre-existing autoantibodies, and presence of common antigens between tumors and normal tissues. This review lists the current biomarkers that might predict irAEs and their possible mechanisms for both nonspecific and organ-specific biomarkers. However, the prediction of irAEs remains a major clinical challenge to screen and identify patients who are susceptible to irAEs and likely to benefit from ICIs.
In recent years, immune checkpoint inhibitors (ICIs) have achieved gratifying effects in a wide variety of tumors, including melanoma , renal cell carcinoma  and non-small cell lung cancer (NSCLC) , which greatly changed the traditional tumor treatment strategy and brought more survival benefits to patients [4, 5]. However, much of the enthusiasm for ICIs is based on long-term survival benefits, which occur in only a few patients. The survival benefit of patients is not only determined by the efficacy but also affected by adverse events. While ICIs represent a new field against cancer, they have also produced a unique set of immune-related adverse events (irAEs) that could have serious or even fatal consequences. Only by improving efficacy and reducing toxicity as much as possible could patient survival be improved.
Undeniably, irAEs are very common, depending on the ICI mechanism. The application of ICIs destroys the mechanism that might protect tissues from autoimmune response damage , enhances the activity of T cells against antigens presented in tumors and healthy tissues , and increases the level of pre-existing autoantibodies and inflammatory factors , leading to a series of irAEs. However, current research on the mechanisms of irAEs is still in the early stage, and there are no recognized and universal mechanisms to explain irAEs. Strikingly, discrete toxicities caused by the nonspecific activation of the immune system could affect almost all tissues and organs. Among them, irAEs of the digestive system, endocrine organs and lungs are more common, and the heart, liver, kidneys, nerves, and eyes are relatively less affected . The major fatal toxicities are cardiotoxicity, neurotoxicity and interstitial pneumonia, which are as high as 45% . In some studies, the reported incidence was as high as 90% for any grade irAEs from ICI monotherapy . A meta-analysis indicated an overall incidence over 70% with anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monotherapy (ipilimumab, IPI)  and 27–78% in phase 3 trials of anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed death ligand-1 (anti-PD-L1) agents [12,13,14]. Serious irAEs could lead to irreversible outcomes. The clinical characteristics of irAEs are relatively hidden with subtle imaging changes and are difficult to determine in the early stage. Therefore, some of the major clinical challenges include the early identification of patients who are susceptible to irAEs before they occur and the monitoring of the development of irAEs. Additionally, the common clinical strategy is mostly the combination of immunotherapy with chemotherapy or targeted therapy, so it is difficult to judge whether the adverse events are caused by immunotherapy alone, which suggests that it is important to accurately identify irAEs. Therefore, it is imperative to develop predictive markers for the occurrence of irAEs, to screen high-risk groups, to monitor the change in irAEs and to judge the outcome of irAEs to further optimize the benefit of patients and minimize the risk of toxicity.
Many factors, such as sex and tumor type, might be able to predict the occurrence of irAEs. From extensive literature reports and clinical experience, it was found that males had a better response than females, but females were more likely to suffer irAEs . Moreover, it is known that females are more susceptible to autoimmune diseases , which might be related to some sex-specific factors. In addition, a meta-analysis suggested that different tumor types had different immune microenvironments that might drive tissue-specific irAEs . For example, dermatitis and arthritis were more common in melanoma patients than in renal cell carcinoma patients, while pneumonia and dyspnea were less common in melanoma patients . However, these factors cannot accurately predict the occurrence of irAEs, making it difficult to achieve the purpose of early screening and early detection. Moreover, most of the previous studies focused on identifying immunotherapy advantage populations, and biomarkers of irAEs could help identify patients susceptible to severe irAEs as exclusion populations for immunotherapy. Therefore, considering the unique clinical value of biomarkers, as well as their convenience and accuracy, we listed the currently known predictive biomarkers of irAEs in this review to help better understand irAEs and provide clinical clues for subsequent studies.
Original articles on irAEs up to January 2020 were screened in Pubmed, Embase and Cochrane library. Medical Subject Headings are used to search for the terms carcinoma, immune checkpoint inhibitor and irAEs, including various adverse events. In this review, two investigators (JPP and XH) independently extracted data. Each study recorded the following information: biomarker, author, year, cancer type, patient number, treatment, correlation between biomarker and irAEs as well as possible hypothesis (Tables 1 and 2 for details). Each study was reviewed several times to ensure that no data was lost or mislabeled. If there are any objections, it was resolved through discussion or a third researcher to decide whether to include or not. For incomplete documents, try to contact the original author to supplement. The quality of included studies was assessed using the Cochrane Hand book 5.1.0 recommended risk of bias assessment tool. Including: (1) random allocation method; (2) allocation concealment; (3) whether to adopt a blind method for the participants and researchers; (4) whether the outcome was assessed by blind method; (5) completeness of outcome data; (6) Selective reporting of outcomes; (7) Other bias. The quality evaluation was conducted independently by two researchers. If there were different opinions, the decision was made through discussion or by referring to the viewpoint of the third researcher.
Potential biomarkers associated with irAEs
IrAEs could be found in all organs, and its forms are also varied between target organs and ICIs. Based on the current data, several potential biomarkers have been identified to predict irAEs, as described below.
In cases of nonspecific symptoms such as fever, cough, and fatigue, it is often difficult to make timely and rapid clinical decisions due to complex screening imaging diagnosis or hematological examination because these are time consuming and require cautious differential diagnosis. Therefore, there is an urgent need to develop easily detectable biomarkers to identify nonspecific irAEs. The known nonspecific biomarkers of irAEs are shown in Table 1, and the possible mechanisms are shown in Fig. 1. Additionally, the quality assessment of the included studies is shown in supplementary Figure 1.
The theory that high C-reactive protein (CRP) levels are closely associated with poor prognosis is well known , and the current research focus has gradually shifted to the relationship between CRP levels and irAEs. A retrospective study found that CRP was increased in patients with irAEs, such as pituitary inflammation, hepatitis, thyroiditis and autoimmune colitis (upper limit of normal (ULN) 5 mg/L), but elevated CRP levels did not correlate with the severity of organ damage . However, this hypothesis still needs to be verified by a larger patient cohort. Currently, the mechanism of the correlation between CRP and irAEs is unclear. CRP, as a representative acute phase reactant, is part of the nonspecific immune mechanism that reflects the presence of systemic inflammation in the host  and represents a high level of immunogenicity and tumor burden. Inflammatory cells could be attracted to sites of neoplasia and may promote cancer cells [36,37,38] which is a typical example of tumor cells conscripting normal cells to enhan ce tumor growth potential. This tumor-promoting inflammation is an important means to acquire the necessary capabilities for tumor cells , which is considered to indicate poor prognosis in many tumors [40, 41]. Additionally, some studies have shown that the elevation in CRP baseline levels was positively associated with the infiltration of CD8+ T cells and regulatory T (Treg) cells , and highly activated effector T cells could activate the systemic inflammatory response, which might be associated with nonspecific irAEs  (Fig. 1a).
CRP as a biomarker has the advantages of easy sample collection, simple measurement and convenient analysis. However, the CRP level is susceptible to a variety of physiological and pathological factors, such as acute or chronic infections, anti-infective and anti-inflammatory drugs and autoimmune diseases, which suggests that a single estimation of the CRP level is not able to accurately and objectively predict irAEs. Therefore, in short, patients were considered to suffer from irAEs if their CRP increased at least twice during the two-week interval, the procalcitonin level was low, and there was no evidence of infection (negative for etiological culture and serology) .
Interleukin − 6
Similar to the association with poor ICI efficacy [42, 43], an important observation was that a high interleukin-6 (IL-6) level after ICI treatment was closely related to irAEs, such as Crohn’s disease  and psoriasiform dermatitis . In contrast, a previous study of malignant melanoma patients using a CTLA-4 inhibitor found that a lower baseline level of IL-6 was strongly associated with the development of irAEs , including colitis . These results indicated that both low baseline IL-6 levels and increased IL-6 levels after ICI treatment might predict the occurrence of irAEs. This might be explained by the important role of IL-6 in inflammation. IL-6 has a two-sided effect on the development of tumors, both preventing tumor formation and promoting tumor progression [42, 45]. IL-6 plays an active role in innate and adaptive immunity, such as the activation of helper T (Th) cells, inhibition of Treg cells, and differentiation of B cells , and these overactive manifestations of the immune system are closely related to irAEs . Another important deduction is the excessive release of inflammatory cytokines . IL-6 plays an important role in the tumor-related systemic inflammatory response, not only as a major inducer of CRP  but also as a direct inducer of anti-inflammatory molecules , which are also considered potential mechanisms by which IL-6 participates in the occurrence of irAEs. The overall hypothesis is shown in Fig. 1a. However, so far, there is no consensus.
Meanwhile, recent studies have shown that the CRP level in peripheral blood might act as a surrogate for IL-6 activity in vivo based on cytokine release syndrome (CRS) after treatment with chimeric antigen receptor T-cells (CAR-T cells) in leukemia . A significant proportion of patients with irAEs had characteristics similar to those of patients with CRS , and IL-6 was significantly increased in CRS [49, 50], which directly demonstrated the effectiveness of IL-6 as an irAE biomarker.
Blood cell count
Blood counts have received widespread attention as a highly available specimen and a signal of irAEs. Fujisawa Y et al., by analyzing the fluctuation of blood counts on or before the day of irAEs in melanoma patients treated with nivolumab, found that the increase in white blood cell counts and the decrease in relative lymphocyte counts were closely related to the incidence of grade 3–4 irAEs, especially pulmonary irAEs . A previous analysis suggested that a higher baseline and increase in absolute lymphocyte counts (ALC) and absolute eosinophil counts (AEC) after ICI treatment were strongly associated with the development of irAEs in patients with solid tumors (including lung cancer, kidney cancer, melanoma, etc.) treated with anti-PD-1 antibodies (baseline ALC > 2000, AEC ≥ 100) . Encouragingly, studies by Nakamura Y et al. in melanoma patients treated with anti-PD-1 antibody showed that AEC > 240/μL at baseline and relative eosinophil count at 1 month > 3.2% could be valuable biomarkers for predicting endocrine irAEs . Conversely, a study by Leila Khoja et al. revealed that in melanoma patients treated with IPI, the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and eosinophil-lymphocyte ratio (ELR) were not associated with toxicity but only with the response to ICI treatment . The reason for this paradox might be the difference in pathological changes caused by different types of ICIs.
Conventional blood cell counts are known to be a crude reflection of the body’s immune state and are crucial in classic cellular, humoral, and tumor immunity (Fig. 1a). However, considering the involvement of different types of ICIs and various affected sites, the mechanism is complex and diverse, and no unified conclusion has been reached yet. Moreover, the blood cell count has certain limitations as a biomarker. Similar to CRP, it is primarily affected by the patient’s inflammatory state, physical condition, recent new infections or other diseases unrelated to the original tumor and to a large extent by myelosuppression due to chemotherapy or radiotherapy. Therefore, the accuracy and reliability of blood cell count as a predictor of irAEs still need to be further weighed and verified.
Cytokines, a kind of small-molecule protein with extensive biological activities, play a crucial role in a variety of life activities, such as innate and adaptive immunity, tumor growth, and the inflammatory response . Among the 40 cytokines/chemokines assessed in plasma, Shaheen Khan et al. found that compared with the baseline level before ICI treatment, the upregulation of various cytokines after ICI treatment, especially induced CXCL9, 10, 11 and 13, was closely related to the occurrence of irAEs . CXCL9/10/11, involved in the establishment of the CXCL9/10/11-CXCR3 axis in the tumor microenvironment, is a chemokine that activates T cells , which could regulate the differentiation, activation and migration of immune cells and effectively inhibit tumor growth  (Fig. 1b). Moreover, previous studies indicated that they were associated with a variety of autoimmune diseases, including thyroiditis, inflammatory bowel disease (IBD), and systemic sclerosis [52, 54]. Therefore, it is considered to be a key cytokine axis closely related to irAEs, but as yet, it has not been observed to be associated with organ-specific irAEs. CXCL 13, as a B-cell chemoattractant, is mainly expressed in mature B-cells, CD4+ follicular Th cells and activated Treg cells [54, 55] and participates in a series of autoimmune and inflammatory diseases, including multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus [56,57,58,59] (Fig. 1b). At the same time, the levels of IL-6, CXCL2, CCL20, CXCL8 and CCL23 in patients with irAEs were also significantly higher than in those without irAEs . Therefore, this might support the hypothesis that ICI treatment induced an excessive immune storm that ultimately led to irAEs. Furthermore, in another retrospective study, the elevation of cytokines was found prior to ICI treatment , which might be in favor of the assumption that ICI treatment triggered a silent subclinical inflammatory response. Remarkably, the complex tumor microenvironment is a critical regulator involved in immune escape, progression, and distant metastasis . High expression of hepatocyte growth factor and colony-stimulating factor-1 (CSF-1) has also been found to promote immune tolerance in the immunosuppressive microenvironment of hepatocellular carcinoma as an inflammation-associated tumor . Interestingly, the study of Lim SY et al. also confirmed that the increased expression of 11 cytokines represented by the CSF, fractalkine, and IL families is closely related to severe irAEs . These cytokines not only have strong pro-inflammatory activity but also participate in the inflammation of various autoimmune diseases [63, 64], so they could predict irAEs to a certain extent. In summary, cytokines are a potential biomarker for predicting irAEs, but no organ specificity has been found.
Tumor mutation burden
Tumor mutation burden (TMB) has been widely promoted as a useful biomarker for predicting the expected therapeutic response of tumors treated with immunotherapy. Then, a challenging question arises: does TMB have the same predictive power for irAEs? A large retrospective analysis of 16,411,749 irAE reports from 5,160,064 patients by David Bomze et al. revealed a significant positive correlation between high TMB and irAEs during anti-PD-1 therapy in a variety of solid tumors . One contributing mechanism is the antigen spreading theory (Fig. 1c). After ICIs are taken, tumor cells die and release antigens, including neoantigens, which results in high TMB . While fighting against neoantigens, T cells could also cross-react with the corresponding wild-type antigens in normal tissues , resulting in damage to normal tissues. The association between high TMB and irAEs was via the release of potential neoantigens, which is consistent with the theory of a positive correlation between high TMB and improved response to anti-PD-1 therapy. Regrettably, however, no studies have shown a link between TMB and organ-specific irAEs or their severity. There is currently no evidence linking TMB to irAEs caused by other ICIs, such as PD-L1 and CTLA-4 inhibitors. These valuable clinical questions are expected to be addressed by further research. In conclusion, high TMB might be a potential biomarker for assessing the risk of irAEs in vulnerable patient groups, but it needs to be validated and further explored in large prospective clinical studies.
Maria Pia Pistillo et al. suggested that higher baseline levels of soluble CTLA-4 (sCTLA-4 > 200 pg/ml) were closely associated with irAEs in melanoma patients treated with IPI, especially gastrointestinal irAEs . One possible hypothesis is based on the dysregulation of autoreactive T cells (Fig. 1d). IPI exerts a powerful antitumor effect by blocking CTLA-4 binding to CD80 and CD86 ligands on antigen-presenting cells, which leads to T cell activation, intracellular congestion, and tumor-specific effects [66, 67]. Maria Pia Pistillo and colleagues suggested that elevated sCTLA-4 levels might block the interactions between full-length CTLA-4 expressed by autoreactive T cells and Tregs as well as B7 ligands, thus enhancing the cytotoxicity of T cells and reducing the immunosuppressive function of Treg cells . In other words, a high level of sCTLA-4 reflects the increase in T cell activation after IPI treatment. In addition, as some previous studies have shown, an increase in sCTLA-4 levels was associated with longer overall survival (OS) in a variety of tumors, such as malignant melanoma , malignant mesothelioma , and NSCLC . Moreover, many studies pointed out that the occurrence of irAEs was positively correlated with a better efficacy of ICIs [42, 70], which also supported that sCTLA-4 might be a promising biomarker for predicting irAEs. However, sCTLA-4 is mainly produced by Treg cells, which are mainly involved in immune escape, and some tumor cells can also produce and release sCTLA-4 into the blood . Therefore, to some extent, a high level of sCTLA-4 could also be used as a marker of tumor immune escape and high tumor burden, which is contradictory to the above theory. Overall, the specific mechanism of sCTLA-4 as a biomarker for predicting irAEs and the association between sCTLA-4 levels and irAE grades still need further exploration.
Not all patients taking ICI treatment will suffer the same irAEs. Real world results have shown a variety of complex conditions, such as organ specificity and drug specificity, which might be influenced by the individual differences of patients, disease characteristics, drug types, regional culture and other mixed factors. Organ-specific irAEs are mainly a discrete toxicity caused by the nonspecific activation of the immune system, which could invade many organs, such as the gastrointestinal tract, endocrine system, and lungs. Different organs have different responses and affinities to ICI treatment. For example, colitis mostly occurs in patients taking IPI, while pneumonitis mostly occurs in patients taking anti-PD-1/PD-L1 . What are the mechanisms of organ-specific irAEs? To date, no consensus has been reached. The hypotheses focus on the excessive release of inflammatory cytokines, overactivation of the immune system, amplification of preexisting abnormal antibodies, and misleading damage caused by the presence of common antigens between tumors and normal tissues. The organ-specific biomarkers of irAEs are shown in Table 2, and the possible mechanisms are shown in Fig. 2. The quality assessment of the included studies is shown in supplementary Figure 2.
Gastrointestinal (GI) irAEs, mainly manifested as diarrhea, colitis, and IBD, are the most common irAEs in ICI treatment [4, 72], especially IPI [73,74,75], and most occur in 2–3 cycles after ICI treatment . In most cases, GI irAEs were tolerable and did not result in the termination of ICI treatment. However, when grade 2–4 diarrhea occurs, effective treatment measures should be taken promptly, and immunotherapy should be terminated if necessary . The main mechanism is based on the hypothesis that ICI triggers the activation of T cells, which in turn leads to an excessive increase in a range of inflammatory cytokines. Currently, biomarkers for predicting GI irAEs are the focus of research. The main biomarkers are as follows, and the possible mechanisms are shown in Fig. 2a.
The disorder of the gut microbiome
It is well known that colitis is closely related to the decrease in the biodiversity of the intestinal microbiome  and the destruction of the host-bacterial ecosystem . A clinical study by high-throughput sequencing of fecal samples from patients with advanced malignant melanoma treated with IPI showed that a significant reduction in the percentage of Firmicutes after immunotherapy, at least 2 times lower than baseline, was associated with immune-related colitis . Intriguingly, the microbiota of patients prone to colitis was rich in Firmicutes at baseline but significantly decreased after ICI treatment, while a higher proportion of Bacteroidetes was present in patients without colitis. However, another study claimed that Bacteroidetes were underrepresented in metastatic melanoma patients with immune-related colitis treated with IPI . Therefore, in short, patients with baseline stool samples without Bacteroidetes and with high levels of Firmicutes were more likely to develop immune-related colitis. A stable microbial system in the gut is essential for maintaining the intestinal epithelial barrier and anti-inflammatory effects , and its disruption leads to impairments in the bacterial polyamine transport system and biosynthesis of thiamine, riboflavin and pantothenate , which might be a potential hypothesis. Bacteroidetes can inhibit inflammation by stimulating Treg cell differentiation [81, 82], so patients lacking Bacteroidetes are more likely to experience a local intestinal inflammatory response. Another proposed mechanism is that the microbial-derived products of intestinal disorders could trigger an in situ immune response that might eventually lead to the activation of self-reactive immune cells , causing local intestinal tissue damage.
CD177 and CEACAM1
Vafa Shahabi et al. analyzed the gene expression profiles of whole blood samples of melanoma patients treated with IPI and found that the neutrophil activation markers CD177 and CEACAM1 were highly expressed at baseline and postbaseline in patients with GI irAEs . Moreover, the increase in CD177 occurred prior to the absolute neutrophil count increase in peripheral blood , indicating that CD177 might be a more sensitive early biomarker. The nonnegligible role of neutrophils in maintaining intestinal balance might support a reasonable hypothesis. CEACAM1 mediates activated neutrophils and other immune cells to adhere to endothelial cells [84, 85] involved in the pathogenesis of immune-mediated intestinal diseases. This could be verified in the colon biopsies of patients with GI irAEs, which revealed focal neutrophilic crypts and neutrophil infiltration in the lamina propria of the affected tissue [28, 86], the most prominent features of active colitis [28, 86]. This pathological change conforms to the theory of autoinflammation; that is, the local tissue inflammation of the host at the anatomical site leads to injury of the target organ . In brief, increases in CD177 and CEACAM1 might be a signal for the occurrence of immune-related colitis.
Peripheral blood mRNA expression (CCL3, CCR3, IL-5, IL-8 and PTGS2)
A retrospective study based on two large clinical trials suggested that peripheral blood gene expression, mainly CCL3, CCR3, IL-5, IL-8 and PTGS2, which are involved in the inflammatory immune response, was closely related to immune-related diarrhea, especially grade 2–4 diarrhea . In addition, previous studies have linked IL-8, CCR3, and CCL3 to diarrhea cases [88,89,90]. Furthermore, IL-8 expression is regulated by IL-17 , a cytokine clearly associated with the development of severe diarrhea/colitis . This further increased the credibility of IL-8 as an irAE biomarker.
IL-17 and human leukocyte antigen allele
Ahmad A. Tarhini et al. reported that upregulation of IL-17 levels at baseline and 6 weeks after ICI treatment showed a noteworthy correlation with grade 3 diarrhea/colitis in melanoma patients treated with IPI . IL-17 is a cytokine with a variety of inflammatory effects including the aggregation of neutrophils  and is one of the upregulated central inflammatory cytokines in IBD . The increase in circulating IL-17 levels, which are usually inhibited by CTLA-4, might be a reflection of patients with subclinical colitis, but ICI intervention disrupts this ecological balance . The inflammatory immune response might be the theoretical basis supporting IL-17 as a biomarker. In general, IL-17 might be developed as a promising biomarker to predict immune-related colitis due to its simple sample acquisition and easy detection.
Additionally, Omar Hasan Ali et al. identified a significant correlation between the human leukocyte antigen (HLA) type II variant HLA-dqb1 * 03:01 and immune-related colitis through the analysis of HLA allele typing . The HLA gene plays a central role in antigen expression and immune tolerance . Currently, the possible mechanism lies in the presence of common antigens between tumors and colon tissues, which enables colon tissues to be recognized by antigen-specific T cells, thus causing colon damage .
Immune-related pneumonia is a change similar to interstitial pneumonia that is severe enough to be life-threatening . Its clinical manifestations are complex and varied, and it is difficult to diagnose early and to distinguish from other pneumonia on imaging. Salahaldin A. Tahir et al. reported that the increase in an autoantibody against CD74 after ICI treatment was notably correlated with immune-related pneumonia, which suggested that CD74 plays an important role . CD74, an autoantibody active protein, is an intracellular chaperone of MHC-II but is expressed on the cell membrane of immune cells, including macrophages  and could stimulate the release of inflammatory mediators . Moreover, there was evidence that the presence of common antigens between tumor cells and lung tissues could enhance the recognition of lung antigens by specific T-cells , thus causing misleading damage to the lungs by the immune system. Alternatively, one new hypothesis was proposed that ICI disrupts the mechanism that inhibits the inflammatory response of Th2 cells in the body. Th2 cells participate in the development of pulmonary interstitial disease and the formation of eosinophils, and under normal circumstances, PD-1 interacts with PD-L2 to suppress the inflammatory response of Th2 cells, while ICI breaks this inhibition, thus producing immune-related pneumonia [97,98,99,100,101]. However, according to a study in children with severe viral pneumonia, CD74+ cells predominate in histopathological types with interstitial pneumonia as the pathological type , but no changes in CD74 have been observed in adults who developed pneumonia without immunotherapy. Therefore, it is reasonable to suspect that the change in CD74 level is specific to immune-associated pneumonia. In brief, the excessive release of inflammatory mediators, misleading damage due to the presence of common antigens between lung and tumor cells, and destruction of the inhibitory mechanism of the inflammatory response might be the causes of immune-related pneumonia (Fig. 2b).
Preexisting abnormal antibodies
Multivariate analysis was conducted on patients with irAEs after ICI treatment, and the presence of preexisting abnormal antibodies, such as rheumatoid factor (RF), antinuclear antibody, antithyroglobulin, and antithyroid peroxidase, was independently correlated with irAEs . Patients with positive RF (RF > 15 IU/mL at pretreatment) were more likely to develop dermal adverse events, and thyroid dysfunction was more common in patients with positive antithyroid antibody, either antithyroglobulin or antithyroid peroxidase at pretreatment . Interestingly, in patients with high PD-L1 expression, the frequency of any existing antibodies and rheumatoid factors was slightly higher, but no significant correlation was observed between antibody expression levels and the severity of irAEs . Some evidence illustrated that patients with abnormal autoantibodies before treatment had a greater chance of producing antibodies . PD-1 is highly expressed in activated B-cells, and B cells are also regulated by T-cell-independent and -dependent mechanisms [103, 104]. T-cells enhance the effect of PD-1 antibody and might in turn induce B-cells to produce autoantibodies, which will lead to the toxic accumulation effect of pre-existing abnormal autoantibodies and finally trigger irAEs [105, 106].
Abnormal TPOAb in thyroid dysfunction
Endocrine toxicity is also a common irAE in immunotherapy. Up to 40% of patients have endocrine toxicity [107, 108], among which thyroid toxicity is the most common , mostly occurring 1–3 months after ICI treatment [109, 110]. Compared with CTLA-4 checkpoint inhibitors, PD-1 inhibitors are more prone to hypothyroidism, while compared with PD-L1 inhibitors, they might lead to the opposite conclusion: hyperthyroidism . Stefano Gay et al. affirmed an interesting association between widespread thyroid hypoechogenicity, decreased thyroid volume, and elevated TPOAb after ICI treatment and thyroid dysfunction in patients with NSCLC or malignant pleural mesothelioma treated with ICIs . This is consistent with the conclusion mentioned above that patients with positive anti-thyroid antibodies are more likely to develop thyroid dysfunction . The decreased thyroid volume might be due to abnormal thyroid function. Additionally, hypoechoic grade and TPOAb elevation have been demonstrated to be a marker of the lymphocytic infiltration of thyroid parenchyma [112, 113]. This also corresponds with the hypothesis that ICIs enhance T cell activity against antigens present in healthy tissues  and increase pre-existing autoantibody levels [105, 106].
Anti-GNAL and anti-ITM2B in Hypophysitis
Hypophysitis is an inflammatory disease of the pituitary gland. The main pathological change is that the pituitary gland is infiltrated by immune cells, resulting in the destruction of endocrine cells and the expansion or atrophy of the pituitary gland [114,115,116]. Pituitary inflammation was more likely to occur with CTLA-4 inhibitors than with PD-1/PD-L1 inhibitors . Similar pathological changes were found in immune-related hypophysitis and autoimmune hypophysitis . Salahaldin A. Tahir et al. took this as inspiration and identified that elevated levels of anti-GNAL and anti-ITM2B autoantibodies (a median of 1.7-fold and 2.5-fold increase for GNAL and ITM2B, respectively, compared to pretreatment samples) might contribute to immune-related hypophysitis by taking advantage of the large-scale screening of autoantibodies in plasma . GNAL and ITM2B, as target proteins expressed in the pituitary gland epithelium, are established as key signal molecules in the normal secretion of various pituitary hormones, such as TRH [119, 120] and ACTH [121, 122], and the increase in anti-GNAL and anti-ITM2B autoantibodies is a manifestation of the destruction of pituitary function. Currently, the prevailing possible mechanism is the qualitative difference in autoreactive effector T cells between anti-PD-1/PD-L1 and anti-CTLA-4 treatment . Anti-CTLA-4 could generate new pituitary reactive effector T cells by activating recent thymic emigrants to diversify the immune response , while anti-PD-1/PD-L1 is more likely to take effect in making existing pituitary reactive effector T cells more active by releasing pre-existing effector T cells . Another hypothesis is that the pituitary endocrine cells themselves might express CTLA-4, making the hypophysis a direct target for anti-CTLA-4 antibodies and causing hypophysis destruction . Furthermore, these results enlighten us that in addition to increased autoantibody levels, disorders of pituitary hormone levels regulated by GNAL and ITM2B, such as TRH and ACTH, as another sign of impaired pituitary function, might also become a promising new research direction to predict pituitary inflammation, but it is expected to be supported by theoretical studies in the future.
Derma-related adverse events mainly present as vitiligo [126, 127], rash and erythema , and cases of Stevens-Johnson syndrome and toxic epidermal necrosis are rarely reported . As mentioned above, patients with preexisting abnormal RF are more likely to have derma-related adverse events after ICI treatment . A retrospective study found that HLA-drb1 *11:01, a common genetic variant of HLA, was observably related to itching . It is worth noting that dermatological irAEs have been demonstrated to imply universal activation of the immune system . One proposed hypothesis is that there are potential shared antigens between tumor cells and normal tissue, such as skin, that could be recognized by antigen-specific T-cells, enhancing T cell recognition of skin antigens , and the HLA gene plays a vital role in antigen expression and immune tolerance , mediating a variety of autoimmune diseases .
Daniel Johnson et al. reported a case of psoriasiform dermatologic toxicity in a melanoma patient that was induced by a PD-1 inhibitor and subsided after treatment with systemic IL-17A blockade . Th17 cells can induce the transcription of IL-17 cytokines, which play a momentous role in a set of autoimmune diseases . However, the blocking of CTLA-4 and PD-1 could increase the expression of Th17 cells in peripheral blood [132, 133]. Based on the crucial role of the Th17/IL17A axis in dermatologic diseases, such as psoriasis, it is hypothesized that ICIs enhance the Th17-mediated immune response in susceptible patients, thus causing some immune-related toxicities.
Many biomarkers have been claimed to predict irAEs, but unfortunately, none is perfect. Currently, research on irAE biomarkers is still in its infancy, with little progress and some deficiencies. First, there is a clinical challenge that some biomarkers are not routine tests in clinical diagnosis and treatment, and the relatively high cost will severely limit their clinical application. Therefore, it is important to develop simple, measurable and accurate biomarkers for personalized patient management. Additionally, by reviewing the biomarkers that predicted irAEs, we found that little is known about the prediction of some fatal irAEs, such as cardiotoxicity, neurotoxicity, and hepatotoxicity. The reasons might be as follows: on the one hand, the incidence of fatal irAEs is low, which leads to a small sample size; on the other hand, the patients cannot cooperate well due to the high mortality and side effects of fatal irAEs. Therefore, these valuable clinical cases are of vital importance and need to be collected and analyzed carefully to solve this problem. Moreover, since the mechanisms of irAEs induced by ICIs are very complex and involve many factors, the discovery of new potential biomarkers will provide insights into the mechanisms of the early prediction and resolution of irAEs in clinical practice. Another key issue is the unicity of irAE treatment. Currently, corticosteroids remain the basis of treatment, and in severe cases, biological immunoregulatory drugs are needed . However, high-dose corticosteroid therapy may bring long-term and potential adverse events to patients, leading to femoral head necrosis, electrolyte disturbance, aggravation of cardiovascular and cerebrovascular diseases, etc. The lack of individualized treatment might delay the effective control of irAEs, and thorough mechanistic research and translational research in the future might provide opportunities for new treatment methods. The well-researched pathogenesis of irAEs might provide more targeted interventions to reduce the systemic adverse reactions caused by hormone shock therapy. At present, some clinical studies attempt to combine some modulators of the immune microenvironment with immunotherapy to further improve the efficacy, such as the Keynote-037 study  and Keynote-252 study . Therefore, the development of drugs to regulate the occurrence of irAEs may be a future research direction that is expected to provide new strategies for the precise treatment of irAEs.
Many studies have shown that patients suffering from irAEs are more likely to achieve a longer survival benefit, which is a signal of lasting efficacy . Therefore, could this correlation be used as evidence to support the deduction that biomarkers related to efficacy could also serve to predict the occurrence of irAEs? Indeed, there are some biomarkers that could predict not only the outcome of receiving ICI therapy but also the occurrence of irAEs. For example, the increase in IL-6 levels could also be used as a nonspecific biomarker to predict irAEs while being associated with poor treatment response . The increased level of sCTLA-4 was applied to predict not only the good antitumor effect of anti-CTLA-4 but also the higher possibility of irAEs . However, there are still some biomarkers, such as soluble PD-L1 (sPD-L1), that are only used to predict the efficacy of immunotherapy in current studies. Increased sPD-L1 levels are significantly linked with better treatment response in patients treated with anti-PD-1 therapy for NSCLC . Conversely, in patients with multiple solid tumors taking PD-1/PD-L1, lower sPD-L1 levels were revealed to be associated with better treatment responses and survival outcomes [138, 139]. Therefore, this paradox still needs to be addressed by a larger cohort, but no relevant studies have yet shown a link between sPD-L1 and irAEs; the connection between them is expected to be revealed in the future. Future research could focus on the discovery of new and convenient markers for predicting the occurrence of irAEs. Moreover, it might also be a good direction to explore biomarkers that can simultaneously predict the reaction efficacy and the occurrence of irAEs, which has crucial clinical value.
Admittedly, there are some limitations to this review. First, since most of the studies we included were retrospective studies, they may lead to certain selection bias and confounding bias. However, this limitation is mostly due to the lack of thorough studies and a series of randomized controlled trials to provide evidence. More prospective studies and further molecular mechanism exploration are expected to make up for this deficiency. In addition, some original literatures are excluded due to lack of sufficient credible evidence and complete experimental protocol and results presentation, which to some extent, may lead to incomplete retrieval of literature. Therefore, in order to understand the biomarkers associated with irAEs as comprehensively as possible, we strictly followed the retrieval strategy to review the literatures.
In conclusion, with the advent of the era of combined immunotherapy, the application scope and treatment population of immunotherapy are expanding. IrAEs, which affect multiple organs, have become a major obstacle to the application prospect of ICIs. The cautious management of irAEs, especially early detection and treatment, can facilitate achieving the maximum clinical benefit from immunotherapy. Extensive interdisciplinary cooperation to provide the best treatment options and the comprehensive consideration of multiple biomarkers to predict irAEs are also keys to the successful delivery of personalized treatment strategies. Additionally, irAEs can be used to screen and exclude people unsuitable for immunotherapy, which may provide another strategy for precise immunotherapy.
Availability of data and materials
Immune checkpoint inhibitor
Non-small cell lung cancer
Immune-related adverse events
Cytotoxic T-lymphocyte antigen-4
Programmed cell death protein 1
Programmed cell death ligand-1
Upper limit of normal
- Treg cell:
T regulatory cells
Interleukin − 6
Helper T cells
Cytokine release syndrome
- CAR -T cells:
Chimeric antigen receptor T- cells
Absolute lymphocyte counts
Absolute eosinophil counts
Inflammatory bowel disease
Tumor mutation burden
Human leukocyte antigen
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56 https://doi.org/10.1056/NEJMoa1709684.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27 https://doi.org/10.1056/NEJMoa1816714.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51 https://doi.org/10.1056/NEJMoa1810865.
Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–47 https://doi.org/10.1038/nrd.2015.35.
Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261 https://doi.org/10.21037/atm.2016.04.01.
Ke W, Zhang L, Dai Y. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs). Thorac Cancer. 2020;11(4):835–9 https://doi.org/10.1111/1759-7714.13341.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68 https://doi.org/10.1056/NEJMra1703481.
Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer. 2018;6(1):90 https://doi.org/10.1186/s40425-018-0408-9.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8 https://doi.org/10.1001/jamaoncol.2018.3923.
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(4):e1568812 https://doi.org/10.1080/2162402X.2019.1568812.
Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13(undefined):211 https://doi.org/10.1186/s12916-015-0455-8.
Maughan BL, Bailey E, Gill DM, Agarwal N. Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol. 2017;7(undefined):56 https://doi.org/10.3389/fonc.2017.00056.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54 https://doi.org/10.1056/NEJMoa1200690.
Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8(undefined):49 https://doi.org/10.3389/fphar.2017.00049.
Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16(1):94 https://doi.org/10.1186/s12967-018-1467-x.
Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Semin Immunopathol. 2019;41(2):165–75 https://doi.org/10.1007/s00281-018-0715-8.
Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–85 https://doi.org/10.1093/annonc/mdx286.
Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol. 2019;145(10):2625–31 https://doi.org/10.1007/s00432-019-03002-1.
Okiyama N, Tanaka R. Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):95–101 https://doi.org/10.2177/jsci.40.95.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 2017;88(2):225–31 https://doi.org/10.1016/j.jdermsci.2017.07.007.
Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2017;8(69):114268–80 https://doi.org/10.18632/oncotarget.23217.
Nakamura Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, Watanabe R, et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 2019;49(5):431–7 https://doi.org/10.1093/jjco/hyy201.
Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63–8 https://doi.org/10.1038/s41416-018-0155-1.
Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2019;25(5):1557–63 https://doi.org/10.1158/1078-0432.Ccr-18-2795.
Bomze D, Hasan Ali O, Bate A, Flatz L. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol. 2019;5(11):1633–5 https://doi.org/10.1001/jamaoncol.2019.3221.
Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, et al. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunol Immunother. 2019;68(1):97–107 https://doi.org/10.1007/s00262-018-2258-1.
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79 https://doi.org/10.1093/annonc/mdx108.
Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med. 2013;11:75 https://doi.org/10.1186/1479-5876-11-75.
Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39 https://doi.org/10.1186/s40425-015-0081-1.
Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8–14 https://doi.org/10.1016/j.ejca.2018.11.009.
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019;116(44):22246–51 https://doi.org/10.1073/pnas.1908079116.
Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376–83 https://doi.org/10.1001/jamaoncol.2018.5860.
Gay S, Rossi G, Corica G, Graziani G, Genova C, Rijavec E, et al. RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study. Endocrine. 2019; https://doi.org/10.1007/s12020-019-01854-8.
Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019;7(6):860–5 https://doi.org/10.1158/2326-6066.Cir-18-0682.
Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer (Oxford, England: 1990). 2017;82:56–65 https://doi.org/10.1016/j.ejca.2017.05.038.
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999;13(11):1382–97 https://doi.org/10.1101/gad.13.11.1382.
Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med. 1999;190(10):1367–70 https://doi.org/10.1084/jem.190.10.1367.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190(10):1375–82 https://doi.org/10.1084/jem.190.10.1375.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70 https://doi.org/10.1016/s0092-8674(00)81683-9.
Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. PloS one. 2015;10(12):e0143080 https://doi.org/10.1371/journal.pone.0143080.
Nakayama T, Saito K, Kumagai J, Nakajima Y, Kijima T, Yoshida S, et al. Higher serum C-reactive protein level represents the immunosuppressive tumor microenvironment in patients with clear cell renal cell carcinoma. Clin Genitourin Cancer. 2018;16(6):e1151–8 https://doi.org/10.1016/j.clgc.2018.07.027.
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–7 https://doi.org/10.1200/jco.2012.41.6750.
Hara M, Nagasaki T, Shiga K, Takahashi H, Takeyama H. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab. Surg Today. 2017;47(4):483–9 https://doi.org/10.1007/s00595-016-1404-7.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6(5):583–8 https://doi.org/10.1038/75068.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81 https://doi.org/10.1093/carcin/bgp127.
Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5):878–88 https://doi.org/10.1016/j.bbamcr.2011.01.034.
Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP. C-Reactive protein and breast cancer: new insights from old molecule. Int J Breast Cancer. 2015;2015:145647 https://doi.org/10.1155/2015/145647.
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–72 https://doi.org/10.1007/s13277-016-5098-7.
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–95 https://doi.org/10.1182/blood-2014-05-552729.
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30 https://doi.org/10.1182/blood-2016-04-703751.
Khoja L, Atenafu EG, Templeton A, Qye Y, Chappell MA, Saibil S, et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792–9 https://doi.org/10.1002/cam4.878.
Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520 https://doi.org/10.1210/er.2006-0044.
Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63(undefined):40–7 https://doi.org/10.1016/j.ctrv.2017.11.007.
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(null):1089–104 https://doi.org/10.1093/brain/awm038.
Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2005;7(5):R1001–13 https://doi.org/10.1186/ar1776.
Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, et al. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol. 2008;180(7):5130–40 https://doi.org/10.4049/jimmunol.180.7.5130.
Armengol MP, Cardoso-Schmidt CB, Fernandez M, Ferrer X, Pujol-Borrell R, Juan M. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J Immunol. 2003;170(12):6320–8 https://doi.org/10.4049/jimmunol.170.12.6320.
Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58(8):2257–67 https://doi.org/10.1002/art.23667.
Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tallaksen C, et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006;108(2):432–40 https://doi.org/10.1182/blood-2005-06-2383.
Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 2017;108(5):1022–31 https://doi.org/10.1111/cas.13226.
Son B, Lee S, Youn H, Kim E, Kim W, Youn B. The role of tumor microenvironment in therapeutic resistance. Oncotarget. 2017;8(3):3933–45 https://doi.org/10.18632/oncotarget.13907.
Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469 https://doi.org/10.1155/2015/731469.
Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31(10):695–703 https://doi.org/10.1089/jir.2011.0065.
Santamaria P. Cytokines and chemokines in autoimmune disease: an overview. Adv Exp Med Biol. 2003;520:1–7 https://doi.org/10.1007/978-1-4615-0171-8_1.
Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):108–91 https://doi.org/10.1158/0008-5472.Can-11-3722.
Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–13 https://doi.org/10.1016/j.coi.2006.01.011.
Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PloS one. 2014;9(2):e87705 https://doi.org/10.1371/journal.pone.0087705.
Roncella S, Laurent S, Fontana V, Ferro P, Franceschini MC, Salvi S, et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother. 2016;65(8):909–17 https://doi.org/10.1007/s00262-016-1844-3.
Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2012;61(9):1463–72 https://doi.org/10.1007/s00262-012-1211-y.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist. 2020;25(4):e679–83 https://doi.org/10.1634/theoncologist.2019-0299.
Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol. 2013;43(5):1274–85 https://doi.org/10.1002/eji.201242529.
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, ROYAL RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283–9 https://doi.org/10.1200/jco.2005.04.5716.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30 https://doi.org/10.1056/NEJMoa1412082.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32 https://doi.org/10.1056/NEJMoa1503093.
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62 https://doi.org/10.1038/nature13904.
Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11 https://doi.org/undefined.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48 https://doi.org/10.1016/j.ejca.2015.11.016.
Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunotherapeutics. 2018;14(9):2178–82 https://doi.org/10.1080/21645515.2018.1442970.
Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391 https://doi.org/10.1038/ncomms10391.
Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol. 2014;176(2):266–74 https://doi.org/10.1111/cei.12277.
Round JL, Mazmanian SK. Inducible Foxp3 þ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci. 2010:12204–9 https://doi.org/10.1073/pnas.0909122107.
Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci Transl Med. 2014;6(220):220ra211 https://doi.org/10.1126/scitranslmed.3008051.
Khan Z, Hammer C, Guardino E, Chandler GS, Albert ML. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach. Genome Med. 2019;11(1):39 https://doi.org/10.1186/s13073-019-0652-8.
Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433–46 https://doi.org/10.1038/nri1864.
Skubitz KM, Skubitz AP. Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells. Biopolymers. 2011;96(1):25–31 https://doi.org/10.1002/bip.21447.
Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204 https://doi.org/10.1186/1479-5876-9-204.
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020; https://doi.org/10.1038/s41571-020-0352-8.
DuPont HL, Ericsson CD, Farthing MJ, Gorbach S, Pickering LK, Rombo L, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16(3):149–60 https://doi.org/10.1111/j.1708-8305.2008.00299.x.
Castor MG, Rezende B, Resende CB, Alessandri AL, Fagundes CT, Sousa LP, et al. The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol. 2010;184(5):2646–54 https://doi.org/10.4049/jimmunol.0902614.
Song DJ, Shim MH, Lee N, YOO Y, CHOUNG JT. CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. Allergy Asthma Immunol Res. 2017;9(4):360–7 https://doi.org/10.4168/aair.2017.9.4.360.
Nardinocchi L, Sonego G, Passarelli F, Avitabile S, Scarponi C, Failla CM, et al. Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. Eur J Immunol. 2015;45(3):922–31 https://doi.org/10.1002/eji.201445052.
Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med (Lausanne). 2019;6:119 https://doi.org/10.3389/fmed.2019.00119.
Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15(7):1090–100 https://doi.org/10.1002/ibd.20894.
Tabchi S, Messier C, Blais N. Immune-mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):269–77 https://doi.org/10.1097/cco.0000000000000291.
Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006;107(12):4807–16 https://doi.org/10.1182/blood-2005-11-4334.
Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1043–7 https://doi.org/10.1001/jamaoncol.2019.0402.
Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56 https://doi.org/10.1038/ni.3049.
Bratke K, Fritz L, Nokodian F, Geißler K, Garbe K, Lommatzsch M, et al. Differential regulation of PD-1 and its ligands in allergic asthma. Clin Exp Allergy. 2017;47(11):1417–25 https://doi.org/10.1111/cea.13017.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–7 https://doi.org/10.1158/1078-0432.Ccr-12-1362.
van der Werf N, Redpath SA, Azuma M, Yagita H, Taylor MD. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9(3):e1003215 https://doi.org/10.1371/journal.ppat.1003215.
Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006;103(31):11695–700 https://doi.org/10.1073/pnas.0601347103.
de Souza Costa VH, Baurakiades E, Viola Azevedo ML, Traiano G, Kowal Rosales J, Kunze Larsen KS, et al. Immunohistochemistry analysis of pulmonary infiltrates in necropsy samples of children with non-pandemic lethal respiratory infections (RSV; ADV; PIV1; PIV2; PIV3; FLU A; FLU B). J Clin Virol. 2014;61(2):211–5 https://doi.org/10.1016/j.jcv.2014.06.026.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51 https://doi.org/10.1016/s1074-7613(00)80089-8.
Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477–83 https://doi.org/10.1038/nm955.
Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34 https://doi.org/10.1212/wnl.0000000000004359.
Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–93 https://doi.org/10.1001/jamaneurol.2016.1399.
Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018;178(2):173–80 https://doi.org/10.1530/eje-17-0810.
Iglesias P. Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach. Eur J Intern Med. 2018;47:6–13 https://doi.org/10.1016/j.ejim.2017.08.019.
Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770–80 https://doi.org/10.1210/jc.2017-00448.
de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101(11):4431–9 https://doi.org/10.1210/jc.2016-2300.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173–82 https://doi.org/10.1001/jamaoncol.2017.3064.
Raber W, Gessl A, Nowotny P, Vierhapper H. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid. 2002;12(8):725–31 https://doi.org/10.1089/105072502760258712.
Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract Res Clin Endocrinol Metab. 2005;19(1):1–15 https://doi.org/10.1016/j.beem.2004.11.003.
Lupi I, Zhang J, Gutenberg A, Landek-Salgado M, Tzou SC, MORI S, et al. From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis. Endocrinology. 2011;152(11):4190–8 https://doi.org/10.1210/en.2011-1004.
Gutenberg A, Buslei R, Fahlbusch R, Buchfelder M, Brück W. Immunopathology of primary hypophysitis: implications for pathogenesis. Am J Surg Pathol. 2005;29(3):329–38 https://doi.org/10.1097/01.pas.0000149707.12335.8e.
Caturegli P. Autoimmune hypophysitis: an underestimated disease in search of its autoantigen(s). J Clin Endocrinol Metab. 2007;92(6):2038–40 https://doi.org/10.1210/jc.2007-0808.
Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19(1):82–92 https://doi.org/10.1007/s11102-015-0671-4.
Lin HH, Gutenberg A, Chen TY, Tsai NM, Lee CJ, Cheng YC, et al. In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis. Sci Rep. 2017;7:43492 https://doi.org/10.1038/srep43492.
Hashimoto K, Zanger K, Hollenberg AN, Cohen LE, Radovick S, Wondisford FE. cAMP response element-binding protein-binding protein mediates thyrotropin-releasing hormone signaling on thyrotropin subunit genes. J Biol Chem. 2000;275(43):33365–72 https://doi.org/10.1074/jbc.M006819200.
Peverelli E, Mantovani G, Lania AG, Spada A. cAMP in the pituitary: an old messenger for multiple signals. J Mol Endocrinol. 2014;52(1):R67–77 https://doi.org/10.1530/jme-13-0172.
Antoni FA, Hunter EF, Lowry PJ, Noble JM, Seckl JR. Atriopeptin: an endogenous corticotropin-release inhibiting hormone. Endocrinology. 1992;130(3):1753–5 https://doi.org/10.1210/endo.130.3.1311248.
Kilger E, Buehler A, Woelfing H, Kumar S, Kaeser SA, Nagarathinam A, et al. BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). J Biol Chem. 2011;286(43):37446–57 https://doi.org/10.1074/jbc.M111.288373.
Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, JOSEPH-PIETRAS D, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254ra128 https://doi.org/10.1126/scitranslmed.3008918.
Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016;85(3):331–9 https://doi.org/10.1111/cen.13063.
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra245 https://doi.org/10.1126/scitranslmed.3008002.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51 https://doi.org/10.1016/s1470-2045(19)30388-2.
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64 https://doi.org/10.1016/s1470-2045(09)70334-1.
Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–82 https://doi.org/10.1002/cncr.27969.
Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018;14(4):247–9 https://doi.org/10.1200/jop.18.00005.
Gutierrez-Arcelus M, Rich SS, Raychaudhuri S. Autoimmune diseases - connecting risk alleles with molecular traits of the immune system. Nat Rev Genet. 2016;17(3):160–74 https://doi.org/10.1038/nrg.2015.33.
Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–98 https://doi.org/10.1056/NEJMra0707449.
Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–78 https://doi.org/10.1097/CJI.0b013e318247a4e7.
von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35 https://doi.org/10.1186/1479-5876-7-35.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68 https://doi.org/10.1200/jco.2017.77.6385.
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97 https://doi.org/10.1016/s1470-2045(19)30274-8.
Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223–30 https://doi.org/10.1200/jco.2018.78.9602.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2) https://doi.org/10.3390/cancers12020473.
Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6(38):41228–36 https://doi.org/10.18632/oncotarget.5682.
Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis. Medicine. 2018;97(3):e9617 https://doi.org/10.1097/md.0000000000009617.
We are grateful to Dr. Si-Zhe Yu of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Jia Hou of the First Affiliated Hospital of Xi’an Jiaotong University for her valuable guidance on writing assistance and manuscript revision.
This work was supported by Targeted Therapy Fund of Chinese Society of Clinical Oncology (Y-sy2018–075 and Y-HR2015–139), Outstanding Youth Project of Shaanxi Province (2020JC-35) and Wu Jieping Medical Foundation (320.6750.19094–51).
Ethics approval and consent to participate
Consent for publication
The authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jia, XH., Geng, LY., Jiang, PP. et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J Exp Clin Cancer Res 39, 284 (2020). https://doi.org/10.1186/s13046-020-01749-x